Evidence map›Paper›PMID 25201346›Full record

ArticleInternational journal of oncology2014

Microarray phosphatome profiling of breast cancer patients unveils a complex phosphatase regulatory role of the MAPK and PI3K pathways in estrogen receptor-negative breast cancers.

Ramon G Manzano, Elena M Martinez-Navarro, Jeronimo Forteza, Antonio Brugarolas

Open access · hybridAbstract read
In one paragraph

Article in International journal of oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ramon G ManzanoMolecular Genetics and Genomics Laboratory, Plataforma de Oncologia, Hospital Quiron Torrevieja, 03184 Torrevieja, Alicante, Spain.
Elena M Martinez-NavarroMolecular Genetics and Genomics Laboratory, Plataforma de Oncologia, Hospital Quiron Torrevieja, 03184 Torrevieja, Alicante, Spain.
Jeronimo FortezaDepartment of Pathology, Plataforma de Oncologia, Hospital Quiron Torrevieja, 03184 Torrevieja, Alicante, Spain.
Antonio BrugarolasDepartment of Medical Oncology, Plataforma de Oncologia, Hospital Quiron Torrevieja, 03184 Torrevieja, Alicante, Spain.
Hospital Quirón Torrevieja · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phosphatases are proteins with the ability to dephosphorylate different substrates and are involved in critical cellular processes such as proliferation, tumor suppression, motility and survival. Little is known about their role in the different breast cancer (BC) phenotypes. We carried out microarray phosphatome profiling in 41 estrogen receptor-negative (ER-) BC patients, as determined by immunohistochemistry (IHC), containing both ERBB2+ and ERBB2- in order to characterize the differences between these two groups. We characterized and confirmed the distinct phosphatome of the two main ER- BC subgroups (in two independent microarrays series) and that of ER+ BC (in three large independent series). Our findings point to the importance of the MAPK and PI3K pathways in ER- BCs as some of the most differentially expressed phosphatases (like DUSP4 and DUSP6) sharing ERK as substrate, or regulating the PI3K pathway (INPP4B, PTEN). It was possible to identify a selective group of phosphatases upregulated only in the ER- ERBB2+ subgroup and not in ER+ (like DUSP6, DUSP10 and PPAPDC1A among others), suggesting a role of these phosphatases in specific BC subtypes, unlike other differentially expressed phosphatases (DUSP4 and ENPP1) that seemed to have a role in multiple BC subtypes. Significant correlation was found at the protein level by IHC between the expression of DUSP6 and phospho-ERK (p=0.04) but not of phospho-ERK with DUSP4. To show the potential prognostic relevance of phosphatases as a functional group of genes, we derived and validated in two large independent BC microarray series a multiphosphatase signature enriched in differentially expressed phosphatases, to predict distant metastasis-free survival (DMFS). ER- ERBB2+, ER- ERBB2- and ER+ BC patients have a distinct pattern of phosphatase RNA expression with a potential prognostic relevance. Further studies of the most relevant phosphatases found in this study are warranted.

Indexed as

Gene Expression ProfilingAdultAgedAged, 80 and overBreast NeoplasmsDisease-Free SurvivalDual Specificity Phosphatase 6Dual-Specificity PhosphatasesFemaleGene Expression Regulation, NeoplasticHumansMicroarray AnalysisMiddle AgedMitogen-Activated Protein Kinase KinasesMitogen-Activated Protein Kinase PhosphatasesPhosphatidylinositol 3-KinasesDual Specificity Phosphatase 6Dual-Specificity PhosphatasesDUSP4 protein, humanDUSP6 protein, humanMitogen-Activated Protein Kinase KinasesMitogen-Activated Protein Kinase PhosphatasesPhosphatidylinositol 3-KinasesReceptors, Estrogen

Identifiers

PMID25201346
PMCPMC4215587
OpenAlexW2088672794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.